Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

Go back to Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
(NASDAQ: RYTM) Delayed: 101.39 +4.60 (4.75%)
Previous Close $96.79    52 Week High
Open $97.80    52 Week Low
Day High $102.14    P/E N/A 
Day Low $97.44    EPS
Volume 1,249,360